Zai Lab Limited

Hello, ladies and gentlemen. Thank you for standing by. Welcome to ZyLab's third quarter 2023 Financial Results Conference call. At this time, all participants are in listen-only mode. Later, we will conduct a question-and-answer session, and instructions will follow at that time. As a reminder, today's conference is being recorded. It is now my pleasure to turn the floor over to Christine Cho, Senior Vice President of Investor Relations. Please go ahead.

Thank you, operator. Good morning, good evening, and welcome to XyLab's third quarter 2023 earnings call. Today's call will be led by Dr. Samantha Du, XyLab's founder, CEO, and chairperson. She will be joined by Josh Smiley, President and Chief Operating Officer, Dr. Rafael Amado, President and Head of Global Oncology Research and Development, Dr. Harold Reinhart, President and Head of Global Development, Neuroscience, Autoimmune, and Infectious Diseases, And Dr. Yajing Chen, Chief Financial Officer. Jonathan Wang, our Chief Business Officer, will also be available to answer questions during the Q&A portion of the call. As a reminder, during today's call, we will be making certain forward-looking statements based on our current expectations. These statements are subject to numerous risks and uncertainties that may cause actual results to differ materially from what we expect due to a variety of factors, including those discussed in our SEC filings. We will also refer to product revenue growth rate on a constant exchange rate basis, which is a non-GAAP financial measure. Please refer to our earnings release furnished with the SEC on November 7th, 2023 for certain disclosures regarding this non-GAAP financial measure. At this time, it is my pleasure to turn the call over to Dr. Samantha Du.

Thank you, Christine. Hello, everyone. Thank you all for joining us today. Throughout the year, we have continued to successfully advance our pipeline, including several important developments for key late-stage programs, such as FEMA, CAR-XT, SODOR, and ASGAR-TJMOT. In the third quarter, we were especially excited about the launch of our fifth commercial product, WISGAR, following months of strategic preparation. Although still early in the launch, we are encouraged by the initial demand for safeguards and by the positive feedback from both physicians and patients. Josh will provide more details on the progress of this very important product launch. We're well positioned to execute on our corporate strategic goals, including the launch of multiple new products and new indications over the next few years. Our pipeline of potential first-in-class and back-in-class products has significant potential to meaningfully improve the lives of patients, and we expect these product candidates to contribute to our long-term growth and drive shareholder value. And with that, I'll pass it to Josh. Josh?